The Monday Brief — Week of Jul 19, 2026

Steel Partners' unsolicited bid at $16.75 per share sent InMode stock surging premarket, valuing the company at roughly $1.1B. The offer triggered a competing proposal from a group led by InMode's CEO—a classic board-shop scenario that could drive the price higher. InMode reaffirmed its FY 2026 guidance of $365M–$375M in revenue and reported Q2 expectations of $95.2M–$95.4M, signaling operational strength amid the takeover noise. Owners watching this should note: consolidation at the equipment-maker level often precedes pricing pressure and channel shifts. Monitor August 5 earnings for any commentary on deal timing and operational impact.

• Steel Partners' cash offer at $16.75/share
• CEO-led group tabled competing proposal
• InMode reaffirmed full-year guidance
• Q2 earnings due August 5

Allergan Aesthetics received EU approval for Boey (trenibotulinumtoxinE), marketed as the first rapid-onset, short-duration neurotoxin for frown lines. The approval adds a new option to an already crowded field—Botox, Dysport, Xeomin, Jeuveau, Nabota, and others—but Boey's faster onset and shorter duration appeal to patients seeking flexibility and minimal commitment. Daewoong's Nabota, meanwhile, crossed ₩1 trillion in cumulative sales, signaling strong global traction. For practice owners, the proliferation of neuromodulator choices means patient education and trial-and-error are now table stakes; expect reps to push Boey hard in Q4 rollout.

• Boey approved in Europe for frown lines
• Rapid onset, short duration differentiation
• Nabota hits ₩1 trillion cumulative sales
• Neuromodulator competition intensifies

Cynosure's XERF monopolar RF platform is gaining rapid adoption across North America and Europe, riding a wave of patient demand for non-invasive skin tightening. The platform is competing directly with Sofwave and other energy-based devices in a market projected to hit $30.81 billion by 2035. Practices are adding XERF and GentleMax Pro laser systems to their arsenals, signaling confidence in RF and laser revenue streams. The trend reflects a broader shift: as neuromodulators commoditize, owners are leaning harder on body contouring, skin tightening, and combination treatments to drive margin and patient lifetime value.

• XERF monopolar RF gaining traction in NA and EU
• Non-invasive skin tightening demand at new highs
• Energy-based device market projected $30.81B by 2035
• Practices bundling RF + laser for higher AUV

GLP-1 aesthetic care is projected to reach $2 billion by 2030, driven by patient interest in weight loss and body contouring synergies. Practices are beginning to integrate GLP-1 patient management (or referral partnerships) with their existing injectables and body-sculpting offerings—a strategic move to capture ancillary revenue and improve patient retention. This is not yet a core med-spa revenue stream, but early movers are positioning themselves as one-stop shops for aesthetic transformation. Owners should evaluate whether GLP-1 patient education and referral partnerships fit their brand and operational capacity.

• GLP-1 aesthetic care market to hit $2B by 2030
• Practices integrating GLP-1 + injectables + body sculpting
• Ancillary revenue and retention opportunity
• Early-mover advantage in patient bundling

Skinvive received FDA approval for the temporary improvement of lines and wrinkles, including "tech neck" lines—a new indication that broadens the injectable's appeal beyond traditional facial areas. The approval reflects growing consumer awareness of neck and décolletage aging and positions Skinvive as a complementary product to neurotoxins and dermal fillers. Owners should train staff on this new indication and consider bundling Skinvive with Botox or filler for neck-and-jawline packages.

• Skinvive FDA approved for tech neck and wrinkles
• New indication expands market appeal
• Bundling opportunity with neurotoxins and fillers
• Patient education critical

Millennials are now nearly matching Gen X shot-for-shot on Botox, signaling a generational shift in preventative aesthetics adoption. This demographic expansion is a tailwind for practices with strong social-media presence and digital marketing. The proliferation of neuromodulator options (seven FDA-approved variants now available) means practices must invest in patient education and provider training to navigate choice architecture. Owners should expect higher patient inquiry volume but also more questions about differences between products.

• Millennials driving preventative botox adoption
• Seven FDA-approved neuromodulators now available
• Patient education and choice architecture critical
• Social-media marketing ROI remains high

L'Oréal raised its stake in Galderma to 20%, signaling confidence in the dermal-filler and injectables maker and further consolidation in the beauty-pharma space. This move underscores the strategic value of aesthetic-device and injectables portfolios to large conglomerates. For practice owners, consolidation at the supplier level can mean pricing pressure, channel shifts, and new go-to-market strategies from acquirers. Stay alert to any announcements about Galderma's product roadmap or distribution changes.

• L'Oréal raises Galderma stake to 20%
• Beauty-pharma consolidation accelerates
• Potential pricing and channel implications
• Monitor Galderma product roadmap announcements

A new study in Nature's Scientific Reports found that Candela's Nordlys non-ablative fractional laser reverses the skin's epigenetic signature of aging—a compelling clinical narrative for patient marketing and provider education. Combined with growing adoption of Candela's GentleMax Pro and GentleMax Pro+ systems, the data supports the value proposition of fractional laser as a foundational anti-aging tool. Owners using Candela platforms should leverage this study in patient consultations and marketing materials.

• Nordlys reverses epigenetic aging signature (Nature study)
• Clinical narrative strengthens patient marketing
• GentleMax Pro adoption accelerating
• Fractional laser remains foundational anti-aging tool

August 5: InMode earnings call—listen for deal commentary, Q3 guidance, and any channel or pricing updates.

Boey rollout: Allergan will begin EU distribution; US timeline unclear. Prepare staff for patient inquiries.

RF platform competition: XERF vs. Sofwave vs. other monopolar RF systems will intensify. Evaluate your current platform and ROI.

GLP-1 partnerships: If you haven't explored GLP-1 referral or management partnerships, now is the time to assess fit and feasibility.